CON-TGO91-210 - CSL Behring
Product names
- AUST R 31810 - CSL CMV IMMUNOGLOBULIN VF (human) 1.5 million units/vial injection
Sponsor
Decision Date
Duration
The consent is effective for all batches manufactured between 1 September 2020 and 30 April 2021.
Non-compliance with standard
The product(s) do not conform with the requirements of TGO 91 but are supplied with label(s) that have been approved by the TGA.
Supply/Import or Export
Supply
Therapeutic good type
Prescription medicines